

	<h2>Botulinum Toxin Guidelines</h2>	
<p><b>Guideline #</b> 6175</p>	<p><b>Categories</b> Clinical → Care Coordination, Care Coordination – Utilization management , TCHP Guidelines</p>	<p><b>This Guideline Applies To:</b> Texas Children's Health Plan</p>
		<p><b>Document Owner</b>  Lisa Fuller</p>

**GUIDELINE STATEMENT:**

Texas Children's Health Plan (TCHP) performs authorization of botulinum toxin injections when used for therapy outside of the guidance documented in the Texas Medicaid Provider Procedure Manual Outpatient Drug Services Handbook.

**DEFINITIONS:**

**Botulinum toxins:** Potent neuromuscular blocking agents that are useful in treating various focal muscle spastic disorders and excessive muscle contractions, such as dystonia, spasms, and twitches.

They produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings. Since the resulting chemical denervation of muscle produces local paresis or paralysis selected muscles can be treated.

Two of the seven naturally occurring serotypes of botulinum toxin have been approved by the FDA for human use in the United States-type A and type B. Due to the unique manufacturing process of each toxin, botulinum toxins are chemically, clinically, and pharmacologically distinct; as a consequence, these products are not interchangeable. The units of biological activity of one botulinum toxin product cannot be compared to or converted into units of any other botulinum toxin product. The established drug names of the botulinum products emphasize the differing dose-to-potency ratios of these products.

The following botulinum toxins are benefits of Texas Medicaid:

- OnabotulinumtoxinA (Botox brand of botulinum toxin type A)
- AbobotulinumtoxinA (Dysport brand of botulinum toxin type A)
- Incobotulinumtoxin A (Xeomin brand of botulinum toxin type A)
- RimabotulinumtoxinB (Myobloc brand of botulinum toxin type B)

## PRIOR AUTHORIZATION GUIDELINES

1. All requests for prior authorization for botulinum toxin injections are received via online submission, fax, phone or mail by the Utilization Management Department and processed during normal business hours.
2. To request prior authorization for medically necessary botulinum toxin injections, the following documentation must be provided:
  - 2.1 Support for the medical necessity of the botulinum toxin injection
  - 2.2 Dosage and frequency of the injections
    - 2.2.1 Requests for Botulinum toxins administered more frequently than every 12 weeks must include documentation of medical necessity stating the need of an interval less than 12 weeks
  - 2.3 Support of the clinical effectiveness of the injections
  - 2.4 Specific site(s) injected
3. The use of botulinum toxin may be considered **medically necessary** for:
  - 3.1 Strabismus
  - 3.2 The treatment of the following disorders if associated with spasticity or dystonia:
    - 3.2.1 Blepharospasm
    - 3.2.2 Cerebral palsy
    - 3.2.3 Facial nerve (VII) dystonia
    - 3.2.4 Hemifacial spasm
    - 3.2.5 Hereditary spastic paraparesis
    - 3.2.6 Idiopathic torsion dystonia
    - 3.2.7 Multiple sclerosis
    - 3.2.8 Neuromyelitis optic
    - 3.2.9 Organic writer's cramp
    - 3.2.10 Orofacial dyskinesia (i.e., jaw closure dystonia)
    - 3.2.11 Schilder's disease
    - 3.2.12 Spasmodic dysphonia or laryngeal dystonia (a disorder of speech due to abnormal control of the laryngeal muscles present only during the specific task of speaking)
    - 3.2.13 Spastic hemiplegia

3.2.14 Spasticity related to stroke, spinal cord injury, or traumatic brain injury

3.2.15 Symptomatic torsion dystonia

3.3 The treatment of other forms of upper motor neuron spasticity

3.3.1 Essential tremor

3.3.2 Achalasia

3.3.3 Anal fissures

3.3.4 Significant drooling in individuals who are unable to tolerate scopolamine or refractory to pharmacotherapy (e.g., anticholinergics).

3.3.5 The treatment of neurogenic overactive bladder (also referred to as detrusor over-activity or detrusor sphincter dyssynergia) that is inadequately controlled with anticholinergic therapy.

3.3.6 The treatment of idiopathic overactive bladder in adults who are unresponsive to or intolerant of a trial of anticholinergic therapy.

3.3.7 The treatment of functional obstruction caused by the inability of the internal anal sphincter to relax in individuals with Hirschsprung disease who have undergone prior surgical treatment.

3.3.8 The treatment of primary axillary, palmar, or gustatory (Frey's syndrome) hyperhidrosis when topical aluminum chloride or other extra strength antiperspirants are ineffective, significant disruption of social life has occurred due to excessive sweating.

4. The use of botulinum toxin may be considered **medically necessary** for the treatment of cervical dystonia (spasmodic torticollis) of moderate or greater severity

4.1 For initial treatment when all of the following criteria are met:4.1.1 History of recurrent clonic or tonic involuntary contractions of one or more of the following muscles: sternocleidomastoid, splenius, trapezius or posterior cervical muscles; **And**

4.1.2 Sustained head tilt or abnormal posturing with limited range of motion in the neck; **And**

4.1.3 The duration of the condition is greater than 6 months.

4.2 Subsequent injections of botulinum toxin for the treatment of cervical dystonia (spasmodic torticollis) of moderate or greater severity are considered medically necessary when:

4.2.1 Response to the initial treatment documented in the medical records; **And**

4.2.2 The individual still meets the medically necessary criteria above.

5. The use of botulinum toxin may be considered **medically necessary** for the prevention of chronic migraine headaches

- 5.1 An initial 6 month trial of botulinum toxin is considered medically necessary when all of the following are met:
- 5.1.1 Adult individual diagnosed with chronic migraine headache; **And**
  - 5.1.2 Fifteen (15) or more headache-days per month with headache lasting 4 hours or longer; **And**
  - 5.1.3 First episode at least 6 months ago; **And**
  - 5.1.4 Symptoms persist despite trials of at least 1 agent in any 2 of the following classes of medications used to prevent migraines or reduce migraine frequency:
    - Antidepressants (for example, amitriptyline, nortriptyline, doxepin); **Or**
    - Beta blocker (for example, propranolol, timolol, metoprolol extended-release); **Or**
    - Antiepileptics (for example, valproate, topiramate, gabapentin)
- 5.2 Continuing treatment with botulinum toxin injection for ongoing prevention of chronic migraine headaches is considered medically necessary for individuals who have previously met criteria above and completed an initial 6 month trial when:
- 5.2.1 Migraine headache frequency was reduced by at least 7 days per month (when compared to pre-treatment average) by the end of the initial trial; **Or**
  - 5.2.2 Migraine headache duration was reduced by at least 100 total hours per month (when compared to the pre-treatment average) by the end of the initial trial.
6. Botulinum toxin is considered **cosmetic and not medically necessary** as a treatment of skin wrinkles or other cosmetic indications.
7. Botulinum toxin is considered **investigational and not medically necessary**:
- 7.1 For the treatment of headache other than chronic migraine meeting the criteria above, including but not limited to tension, episodic migraine (14 migraine days per month or less), or chronic daily headaches.
  - 7.2 For the treatment of individuals with Hirschsprung disease when the criteria above are not met.
  - 7.3 The use of botulinum toxin, whether the same or a different product, following **failure** of an initial trial for the treatment of a medically necessary condition (as listed above) is considered investigational and not medically necessary. *Note: when the initial product was stopped due to a product specific intolerance or allergic reaction (rather than clinical failure), this investigational and not medically necessary statement does not apply.*
  - 7.4 As a treatment for conditions listed above when criteria are not met and for all other conditions not addressed above, including, but not limited to, the following:
    - 7.4.1 Anismus (pelvic floor dyssynergia)
    - 7.4.2 Behcet's syndrome

- 7.4.3 Benign prostatic hyperplasia
- 7.4.4 Brachial plexus palsy
- 7.4.5 Carpal tunnel syndrome
- 7.4.6 Chronic motor tic disorder
- 7.4.7 Disorders of the esophagus (except as listed above in the medically necessary section)
- 7.4.8 Epicondylitis
- 7.4.9 Fibromyalgia/fibromyositis
- 7.4.10 Gastroparesis
- 7.4.11 Low back pain
- 7.4.12 Myofascial pain syndrome
- 7.4.13 Neck pain not related to conditions mentioned above
- 7.4.14 Acquired Nystagmus
- 7.4.15 Parkinson's disease
- 7.4.16 Post-mastectomy reconstruction syndrome
- 7.4.17 Reynaud's syndrome
- 7.4.18 Sphincter of Oddi dysfunction
- 7.4.19 Stuttering
- 7.4.20 Tics associated with Tourette's Syndrome
- 7.4.21 Tinnitus
- 7.4.22 Tourette's Syndrome
- 7.4.23 Tremors
- 7.4.24 Urinary and anal sphincter dysfunction (except as listed above in the medically necessary section)
- 7.4.25 Vaginismus
- 7.4.26 Whiplash-related disorders
- 7.4.27 Zygomatic fractures

8. Requests that do not meet the criteria established by this procedure will be referred to a TCHP Medical Director/Physician Reviewer for review and the Denial Policy may be followed.

9. Preauthorization is based on medical necessity and not a guarantee of benefits or eligibility. Even if preauthorization is approved for treatment or a particular service, that authorization applies only to the medical necessity of treatment or service. All services are subject to

benefit limitations and exclusions. Providers are subject to State and Federal Regulatory compliance and failure to comply may result in retrospective audit and potential financial recoupment.

## REFERENCES:

Texas Medicaid Provider Procedures Manual, Accessed November 10, 2024

[TMPPM.book \(tmhp.com\)](https://www.tmhpa.com/tmppm-book)

Simpson, David M., Hallett, Mark, Ashman, Eric J., Comella, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. American Academy of Neurology, April 18, 2016. Reaffirmed April 30, 2022.

<https://www.neurology.org/doi/10.1212/wnl.0000000000002560>

## Peer Reviewed Publications:

Glader L, Delsing C, Hughes A et al. Sialorrhea in cerebral palsy. American Academy for Cerebral Palsy and Developmental Medicine Care Pathways. Milwaukee, WI; AACPDM; 2019. Available at: <https://www.aacpdm.org/publications/care-pathways/sialorrhea>. Accessed August 15, 2024.

Smith CC, Pariser D. Primary focal hyperhidrosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed May 2024.

Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol. 2000;42(6):1026-1029.

Dressler D, Saberi FA, Benecke R. Botulinum toxin type B for treatment of axillary hyperhidrosis. J Neurol. 2002;249:1729-1732.

Baumann LS, Helam ML. Botulinum toxin-B and the management of hyperhidrosis. Dermatology. 2004;22:60-65.

Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: One-year clinical follow-up. Eur J Neurol. 2000;7(1):55-62.

Nelson L, Bachoo P, Holmes J. Botulinum toxin type B: A new therapy for axillary hyperhidrosis. Br J Plast Surg. 2005;58(2):228-232.

Moawad EM, Abdallah EA. Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life. Glob Pediatr Health. 2015 Jun 8;2:2333794X15590149. doi: 10.1177/2333794X15590149. PMID: 27335961; PMCID: PMC4784590.

Orsini M, Leite MA, Chung TM, Bocca W, de Souza JA, de Souza OG, Moreira RP, Bastos VH, Teixeira S, Oliveira AB, Moraes Bda S, Matta AP, Jacinto LJ. Botulinum Neurotoxin Type A in Neurology: Update. Neurol Int. 2015 Sep 24;7(2):5886. doi: 10.4081/ni.2015.5886. PMID: 26487928; PMCID: PMC4591494.

Alberty J, Oelerich M, Ludwig K, et al. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. *Laryngoscope*. 2000; 110(7):1151-1156.

Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. *Am J Ther*. 2006; 13(3):183-187.

Aurora SK, Dodick DW, Diener HC, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. *Acta Neurol Scand*. 2014; 129(1):61-70.

Aurora SK, Dodick DW, Turkel CC, et al.; PREEMPT 1 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalgia* 2010; 30(7):793-803.

Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. *Headache*. 2007; 47(4):486-499.

Basciani M, Intiso D. Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy. *Pediatr Rehabil*. 2006; 9(2):165-170.

Basson S, Charlesworth P, Healy C, et al. Botulinum toxin use in paediatric colorectal surgery. *Pediatr Surg Int*. 2014;30(8):833-838.

Benecke R. Xeomin in the treatment of cervical dystonia. *Eur J Neurol*. 2009; 16 Suppl 2:6-10.

Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. *Headache*. 2008; 48(2):210-220.

Braker C, Yariv S, Adler R, et al. The analgesic effect of botulinum-toxin A on postwhiplash neck pain. *Clin J Pain*. 2008; 24(1):5-10.

Brant C, Moraes-Filho JP, Siqueira E, et al. Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia. *Dis Esophagus*. 2003; 16(1):33-38.

Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. *Neurology*. 2001; 56(11):1523-1528.

Brisinda G, Maria G, Bentivoglio AR, et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. *N Engl J Med*. 1999; 341(2):65-69.

Brubaker L, Gousse A, Sand P, et al. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. *Int Urogynecol J*. 2012; 23(8):1017-1025.

Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. *Headache*. 2008; 48(6):900-913.

Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. *Neurology*. 2013; 81(9):841 -848.

Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. *Eur Urol*. 2013; 64(2):249-256.

Chen RS, Lu CS, Tsai CH. Botulinum toxin A injection in the treatment of hemifacial spasm. *Acta Neurol Scand*. 1996; 94(3):207-211.

Chen YH, Kuo HC. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. *Urol Int*. 2004; 73(2):156-161.

Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. *Pain*. 1994; 59(1):65-69.

Childers MK, Wilson DJ, Gnatz SM, et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. *Am J Phys Med Rehabil*. 2002; 81(10):751-759.

Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. *Eur Urol*. 2011; 60(4):742-750.

DeMatteo C, Bain JR, Galea V, Gjertsen D. Botulinum toxin as an adjunct to motor learning therapy and surgery for obstetrical brachial plexus injury. *Dev Med Child Neurol*. 2006; 48(4):245-252.

De Seze M, Petit H, Gallien P, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. *Eur Urol*. 2002; 42(1):56-62.

Desiato MT, Risina B. The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy. *Pediatr Rehabil*. 2001; 4(1):29-36.

Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalgia*. 2010; 30(7):804-814.

Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. *J Urol*. 2010; 184(6):2416-2422.



Dodick DW, Mauskop A, Elkind AH, et al.; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. *Headache*. 2005; 45(4):315-324.

Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010; 50(6):921-936.

Dowson C, Sahai A, Watkins J, et al. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. *Int J Clin Pract*. 2011; 65(6):698-704.

Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009; 16 Suppl 2:2-5.

Espandar R, Heidari P, Rasouli MR, et al. Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial. *CMAJ*. 2010; 182(8):768-773.

Evers S. Investigating prophylactic botulinum toxin type A for chronic headache disorders. *Expert Opin Investig Drugs*. 2006; 15(10):1161-1166.

Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2004; 24(10):838-843.

Ezaki M, Malunpaishrope K, Harrison RJ, et al. Onabotulinum toxinA injection as an adjunct in the treatment of posterior shoulder subluxation in neonatal brachial plexus palsy. *J Bone Joint Surg Am*. 2010; 92(12):2171-2177.

Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. *Am J Phys Med Rehabil*. 2002; 81(12):936-942.

Foley N, Pereira S, Salter K, et al. Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis. *Arch Phys Med Rehabil*. 2013; 94(5):977-989.

Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. *Neurology*. 2001; 56(10):1290-1293.

Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. *Headache*. 2008; 48(2):201-209.

Friedenberg F, Gollamudi S, Parkman HP. The use of botulinum toxin for the treatment of gastrointestinal motility disorders. *Dig Dis Sci*. 2004; 49(2):165-175.

Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. *Obstet Gynecol*. 2004; 104(5 Pt 1):922-925.

Guyuron B, Reed D, Kriegler JS, et al. A placebo-controlled surgical trial of the treatment of migraine headaches. *Plast Reconstr Surg*. 2009; 124(2):461-648.

Han-Geurts IJ, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. *J Pediatr Gastroenterol Nutr*. 2014; 59(5):604-607.

Hayton MJ, Santini AJ, Hughes PJ, et al. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. *J Bone Joint Surg Am*. 2005; 87(3):503-507.

Heise CO, Goncalves LR, Barbosa ER, Gherpelli JL. Botulinum toxin for treatment of cocontractions related to obstetrical brachial plexopathy. *Arq Neuropsiquiatr*. 2005; 63(3A):588-591.

Hukkinen M, Koivusalo A, Rintala RJ, Pakarinen MP. Restorative proctocolectomy with J-pouch ileoanal anastomosis for total colonic aganglionosis among neonates and infants. *J Pediatr Surg*. 2014; 49(4):570-574.

Immerman I, Valencia H, DiTaranto P, et al. Subscapularis slide correction of the shoulder internal rotation contracture after brachial plexus birth injury: technique and outcomes. *Tech Hand Up Extrem Surg*. 2013; 17(1):52-56.

Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. *Eur J Neurol*. 2009; 16 Suppl 2:14-18.

Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—a randomized trial. *Mov Disord*. 2011; 26(8):1521-1528.

Jankovic J, Schwartz K, Clemence W, et al. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. *Mov Disord*. 1996; 11(3):250-256.

Jongerius PH, van den Hoogen FJ, van Limbeek FJ, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. *Pediatrics*. 2004; 114(3):620-627.

Jost WH. One hundred cases of anal fissure treated with botulinum toxin: early and long-term results. *Dis Colon Rectum*. 1997; 40(9):1029-1032.

Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. *Clin Neuropharmacol*. 2009; 32(5):259-265.

Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. *J Rehabil Med*. 2011; 43(6):486-492.

Kayikcioglu A, Erk Y, Mavili E, et al. Botulinum toxin in the treatment of zygomatic fractures. *Plast Reconstr Surg*. 2003; 111(1):341-346.

- Keizer SB, Rutten HP, Pilot P, et al. Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. *Clin Orthop Relat Res*. 2002; 401:125-131.
- Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. *Urology*. 2013; 81(3):491-497.
- Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. *J Headache Pain*. 2014; 15:54.
- Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinum toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. *Am J Phys Med Rehabil*. 1998; 77(6):510-515.
- Koivusalo AI, Pakarinen MP, Rintala RJ. Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung's disease. *Pediatr Surg Int*. 2009; 25(10):873-876.
- Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. *Neurology*. 2003; 61(9):1279-1281.
- Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. *Neurology*. 2011; 77(15):1465-1472.
- Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in Parkinsonism. *Mov Disord*. 2003; 18(6):685-688.
- Marberger M, Chartier-Kastler E, Egerdie B, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. 2013; 63(3):496-503.
- Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. *Urology*. 2003; 62(2):259-265.
- Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. *Clin Neuropharmacol*. 2009; 32(5):259-265.
- Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized double-blind, placebo-controlled trial. *Headache*. 2005; 45(4):293-307.
- McVary KT, Roehrborn CG, Chartier-Kastler E, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*. 2014; 192(1):150-156.

- Michaud LJ, Louden EJ, Lippert WC, et al. Use of botulinum toxin type A in the management of neonatal brachial plexus palsy. *PM R*. 2014; 6(12):1107-1119.
- Mikaeli J, Bishehsari F, Montazeri G, et al. Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial. *Aliment Pharmacol Ther*. 2006; 24(6):983-989.
- Miller LS, Parkman HP, Schiano TD, et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. *Dig Dis Sci*. 1996; 41(10):2025-2031.
- Minkes RK, Langer JC. A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease. *J Pediatr Surg*. 2000; 35(12):1733-1736.
- Nicol AL, Wu II, Ferrante FM. Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design. *Anesth Analg*. 2014; 118(6):1326-1335.
- Nitti VW, Dmochowski R, Herschorn S, et al.; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol*. 2013; 189(6):2186-2193.
- Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. *Neurology*. 2004; 62(1):37-40.
- Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. *Cephalalgia*. 2004; 24(1):60-65.
- Pacik PT. OnabotulinumtoxinA as part of a multimodal program to treat vaginismus. *J Appl Biobeh Res*. 2015; 25-36.
- Padberg M, de Bruijn, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. *Cephalalgia*. 2004; 24(8):675-680.
- Padberg M, de Bruijn SF, Tavy DL. Neck pain in chronic whiplash syndrome treated with botulinum toxin. A double-blind, placebo-controlled clinical trial. *J Neurol*. 2007; 254(3):290-295.
- Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. *Neurology*. 1995; 45(4):822-824.
- Park DS, Cho TW, Lee YT, et al. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. *Yonsei Med J*. 2006; 47(5):706-714.
- Pasricha PJ, Miskovsky EP, Kalloo AN. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. *Gut*. 1994; 35(9):1319-1321.
- Patki PS, Hamid R, Arumugam K, et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. *BJU Int*. 2006; 98(1):77-82.

- Patrus B, Nasr A, Langer JC, Gerstle JT. Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease. *J Pediatr Surg*. 2011; 46(1):184-187.
- Placzek R, Drescher W, Deuretzbacher G, et al. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. *J Bone Joint Surg Am*. 2007; 89(2):255-260.
- Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. *Pain*. 2000; 85(1-2):101-105.
- Price AE, Ditaranto P, Yaylali I, et al. Botulinum toxin type A as an adjunct to the surgical treatment of the medial rotation deformity of the shoulder in birth injuries of the brachial plexus. *J Bone Joint Surg Br*. 2007; 89(3):327-329.
- Reid SM, Johnstone BR, Westbury C, et al. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. *Dev Med Child Neurol*. 2008; 50(2):123-128.
- Relja M, Poole AC, Schoenen J, et al.; European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. *Cephalalgia*. 2007; 27(6):492-503.
- Relja M, Telarovic S. Botulinum toxin in tension-type headache. *J Neurol*. 2004; 251 Suppl 1:112-114.
- Repka MX, Savino PJ, Reinecke RD. Treatment of acquired nystagmus with botulinum neurotoxin A. *Arch Ophthalmol*. 1994; 112(10):1320-1324.
- Rollnik JD, Hierner R, Schubert M, et al. Botulinum toxin treatment of cocontractions after birth-related brachial plexus lesions. *Neurology*. 2000; 55(1):112-114.
- Rollnik JD, Karst M, Fink M, Dengler R. Botulinum toxin type A and EMG: a key to the understanding of chronic tension-type headaches? *Headache*. 2001; 41(10):985-989.
- Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind placebo-controlled study. *Headache*. 2000; 40(4):300-305.
- Rosales RL, Kong KH, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. *Neurorehabil Neural Repair*. 2012; 26(7):812-821.
- Saper JR, Mathew NT, Loder EW, et al.; BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. *Pain Med*. 2007; 8(6):478-485.

- Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. *Headache*. 2001; 41(7):658-664.
- Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. *Neurourol Urodyn*. 2006; 25(2):110-115.
- Schulte-Mattler WJ, Krack P.; BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. *Pain*. 2004; 109(1-2):110-114.
- Schulte-Mattler WJ, Martinez-Castrillo JC. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations. *Eur J Neurol*. 2006; 13 Suppl 1:51-54.
- Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment of neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. *J Urol*. 2005; 174(1):196-200.
- Shafik A, El-Sibai O. Vaginismus: results of treatment with botulinum toxin. *J Obstet Gynaecol*. 2000; 20(3):300-302.
- Shulendler AJ, Lee S, Siu M. et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Pharmacotherapy*. 2009; 29(7):784-791.
- Silberstein SD, Göbel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. *Cephalalgia*. 2006; 26(7):790-800.
- Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. *Headache*. 2000; 40(6):445-450.
- Silberstein SD, Stark SR, Lucas SM, et al.; BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized double-blind, placebo-controlled trial. *Mayo Clin Proc*. 2005; 80(9):1126-1137.
- Simpson DM, Gracies JM, Yablon SA, et al.; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. *J Neurol Neurosurg Psychiatry*. 2009; 80(4):380-385.
- Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. *Clin Rehabil*. 2000; 14(1):5-13.
- Smuts JA, Baker MK, Smuts HM, et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. *Eur J Neurol*. 1999; 6(Suppl 4):S99-S102.

Stidham KR, Solomon PH, Roberson JB. Evaluation of botulinum toxin A in the treatment of tinnitus. *Otolaryngol Head Neck Surg.* 2005; 132(6):883-889

Storr M, Allescher HD, Rosch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up. *Gastrointest Endosc.* 2001; 54(6):754-759.

Straube A, Empl M, Ceballos-Baumann A, et al.; Dysport Tension-Type Headache Study Group. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. *Eur J Neurol.* 2008; 15(3):205-213.

Tomsak RL, Remler BF, Averbuch-Heller L, et al. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. *Am J Ophthalmol.* 1995; 119(4):489-496.

Vaezi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. *Gut.* 1999; 44(2):231 -239.

Visco AG, Brubaker L, Richter HE, et al.; Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. *N Engl J Med.* 2012; 367(19):1803-1813.

Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. *Muscle Nerve.* 1998; 21(12):1740-1747.

Wehrmann T, Schmitt TH, Arndt A, et al. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. *Aliment Pharmacol Ther.* 2000; 14(11):1469-1477.

Wehrmann T, Seifert H, Seipp M, et al. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. *Endoscopy.* 1998; 30(8):702-707.

Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. *Am J Obstet Gynecol.* 2005; 192(5):1735-1740.

Wester T, Granström AL. Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease. *Pediatr Surg Int.* 2015; 31(3):255-259.

Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal myofascial pain syndrome. *Spine.* 1998; 23(15):1662-1667.

Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. *Pain.* 2001; 94(3):255-260.

Wohlfarth K, Müller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. *Clin Neuropharmacol.* 2007; 30(2):86-94.

Wong SM, Hui AC, Tong PY, et al. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2005; 143(11):793-797.

Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. *Pain Med.* 2010; 11(12):1827-1833.

<b>Status</b>	<b>Date</b>	<b>Action</b>
Approved	12/31/2024	Clinical & Administrative Advisory Committee Reviewed and Approved for Implementation

Original Document Creation Date: 10/21/2016	This Version Creation Date: 02/23/2024	Effective/Publication Date: 03/01/2024
---	--	--